Listar por autor "Gogas, H."
Mostrando ítems 1-2 de 2
-
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
Fountzilas, G.; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, P.; Karanikiotis, C.; Bafaloukos, D.; Kosmidis, P.; Samantas, E.; Varthalitis, I.; Pavlidis, N.; Pectasides, D.; Dimopoulos, M. A. (2014)Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ... -
Melanoma: The Radiotherapeutic point of view; review of the current literature
Zygogianni, A.; Kyrgias, G.; Kouvaris, J.; Mystakidou, K.; Gogas, H.; Kouloulias, V. (2011)Surgery remains the mainstay of melanoma therapy at all sites. Melanoma is widely believed to be a radioresistant tumor, a misconception that has historically led to the limited use of RT for its treatment. We searched ...